Equities analysts predict that Crispr Therapeutics AG (NASDAQ:CRSP) will post sales of $59.43 million for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Crispr Therapeutics’ earnings, with the highest sales estimate coming in at $76.70 million and the lowest estimate coming in at $14.30 million. Crispr Therapeutics reported sales of $120,000.00 during the same quarter last year, which indicates a positive year-over-year growth rate of 49,425%. The company is expected to report its next earnings results on Monday, February 24th.

According to Zacks, analysts expect that Crispr Therapeutics will report full-year sales of $272.00 million for the current year, with estimates ranging from $226.90 million to $289.27 million. For the next fiscal year, analysts forecast that the company will post sales of $30.04 million, with estimates ranging from $2.03 million to $58.10 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million during the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%.

Several research firms have recently issued reports on CRSP. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $104.00 price target on shares of Crispr Therapeutics in a research report on Monday, December 16th. Oppenheimer boosted their target price on Crispr Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, November 25th. BidaskClub lowered Crispr Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 13th. Zacks Investment Research lowered Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. Finally, Chardan Capital reissued a “buy” rating and issued a $72.50 target price on shares of Crispr Therapeutics in a research report on Monday, November 18th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $71.38.

Shares of CRSP traded down $0.74 during trading hours on Thursday, hitting $66.01. The company had a trading volume of 999,939 shares, compared to its average volume of 985,513. The firm has a fifty day moving average price of $64.60 and a 200-day moving average price of $50.48. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. The stock has a market capitalization of $3.68 billion, a price-to-earnings ratio of -19.19 and a beta of 3.31. Crispr Therapeutics has a 52-week low of $26.00 and a 52-week high of $74.00.

In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares in the company, valued at approximately $2,353,260. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total value of $390,000.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at $390,000. The disclosure for this sale can be found here. In the last three months, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is owned by insiders.

A number of large investors have recently added to or reduced their stakes in the stock. Millennium Management LLC purchased a new stake in Crispr Therapeutics during the 3rd quarter valued at $4,366,000. Orbimed Advisors LLC purchased a new stake in Crispr Therapeutics during the 3rd quarter valued at $21,167,000. Granahan Investment Management Inc. MA grew its position in Crispr Therapeutics by 8.3% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 34,582 shares of the company’s stock valued at $1,418,000 after acquiring an additional 2,655 shares during the last quarter. Barclays PLC grew its position in Crispr Therapeutics by 42.7% in the 3rd quarter. Barclays PLC now owns 13,877 shares of the company’s stock valued at $568,000 after acquiring an additional 4,151 shares during the last quarter. Finally, Stifel Financial Corp grew its position in Crispr Therapeutics by 18.0% in the 3rd quarter. Stifel Financial Corp now owns 9,795 shares of the company’s stock valued at $400,000 after acquiring an additional 1,491 shares during the last quarter. Institutional investors own 49.82% of the company’s stock.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

See Also: Depreciation

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link